Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Ofatumumab Plus Hypercvad/MA Induction Leads to High Rates of Minimal Residual Disease (MRD) Negativity in Patients with Newly Diagnosed Mantle Cell Lymphoma, Results of a Phase 2 Study

Pallawi Torka, MD, Nishitha Reddy, MD, Adrienne Groman, MS, Angela Kader, Jenna Nichols, Alan Hutson, Cory Mavis, MSc, Joseph Dennis Tario, PhD, Paul K. Wallace, MS, PhD, AnneMarie W. Block, PhD, Sheila N. J. Sait, PhD, Bora E Baysal, MD PhD, Vishala T. Neppalli, MD, Suchitra Sundaram, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2019) 134 (Supplement_1): 2817.

https://doi.org/10.1182/blood-2019-123488

Published: 2019

Journal Articles

RNA Editing By APOBEC3A Confers Dynamic Mutational Load in Monocytic Leukemias

Bora E Baysal, MD PhD, Shraddha Sharma, PhD, Jianmin Wang, PhD, Eduardo Cortes-Gomez, M.S, Scott Portwood, MS, Eunice S. Wang, MD

Blood (2017) 130 (Supplement 1): 3939.

https://doi.org/10.1182/blood.V130.Suppl_1.3939.3939

Published: 2017

Journal Articles

A Phase 1/2 Study of Carfilzomib Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide (C-RICE) in Patients with Transplant-Eligible, Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Pallawi Torka, MD, Seema Bhat, Kelvin P. Lee, MD, Alan Hutson, Jenna Nichols, Angela Kader, Cory Mavis, MSc, AnneMarie W Block, Sheila N. J. Sait, PhD, Bora E Baysal, MD PhD, Fadi Habib, MD, Vishala T. Neppalli, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2017) 130 (Supplement 1): 2822.

https://doi.org/10.1182/blood.V130.Suppl_1.2822.2822

Published: 2017

Journal Articles

The Anti-HIV-1 Cytidine Deaminase APOBEC3G Is a Cellular Site-Specific RNA Editing Enzyme

Bora E. Baysal, MD PhD, Santosh Patnaik, MD PhD, Robert T Taggart, PhD, Shraddha Sharma, PhD

Blood (2016) 128 (22): 547.

https://doi.org/10.1182/blood.V128.22.547.547

Published: 2016

Journal Articles

Oxygen Sensing By Succinate Dehydrogenase Regulates Transcriptional Response to Hypoxia in Monocytes

Bora E. Baysal, MD PhD, Shraddha Sharma, PhD, Robert T Taggart, PhD, Santosh Patnaik, MD PhD

Blood (2015) 126 (23): 998.

https://doi.org/10.1182/blood.V126.23.998.998

Published: 2015

NARROW

Ofatumumab Plus Hypercvad/MA Induction Leads to High Rates of Minimal Residual Disease (MRD) Negativity in Patients with Newly Diagnosed Mantle Cell Lymphoma, Results of a Phase 2 Study

RNA Editing By APOBEC3A Confers Dynamic Mutational Load in Monocytic Leukemias

A Phase 1/2 Study of Carfilzomib Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide (C-RICE) in Patients with Transplant-Eligible, Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

The Anti-HIV-1 Cytidine Deaminase APOBEC3G Is a Cellular Site-Specific RNA Editing Enzyme

Oxygen Sensing By Succinate Dehydrogenase Regulates Transcriptional Response to Hypoxia in Monocytes

Email alerts

ASH Publications

American Society of Hematology

Ofatumumab Plus Hypercvad/MA Induction Leads to High Rates of Minimal Residual Disease (MRD) Negativity in Patients with Newly Diagnosed Mantle Cell Lymphoma, Results of a Phase 2 Study

RNA Editing By APOBEC3A Confers Dynamic Mutational Load in Monocytic Leukemias

A Phase 1/2 Study of Carfilzomib Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide (C-RICE) in Patients with Transplant-Eligible, Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

The Anti-HIV-1 Cytidine Deaminase APOBEC3G Is a Cellular Site-Specific RNA Editing Enzyme

Oxygen Sensing By Succinate Dehydrogenase Regulates Transcriptional Response to Hypoxia in Monocytes

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only